Deciphering the Neuroprotective Action of Bee Venom Peptide Melittin: Insights into Mechanistic Interplay

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, are characterized by progressive loss of neuronal structure and function. These conditions often lead to cognitive decline, motor dysfunction, and ultimately severe impairment of daily activities. A key feature of neurodegenerative diseases is chronic inflammation, which contributes to neuronal damage and exacerbates disease progression. Traditional treatments mainly focus on symptomatic relief rather than addressing the underlying causes, highlighting the need for novel therapeutic approaches. Melittin, a bioactive peptide derived from bee venom, has garnered attention for its multifaceted neuroprotective properties, particularly in the context of neuroinflammatory and neurodegenerative disorders. This review delves into the molecular mechanisms through which melittin exerts neuroprotective effects, with a focus on its ability to modulate neuroinflammation, apoptosis, and neurogenesis. Research indicates that melittin can downregulate pro-apoptotic pathways by inhibiting calpain-mediated activation of apoptosis-inducing factor and Bax, thereby reducing neuronal cell death. Additionally, melittin exerts its neuroprotective effects through the inhibition of neuroinflammatory processes, specifically by downregulating key inflammatory pathways such as NF-κB and MAPK. This modulation leads to decreased production of proinflammatory cytokines and prostaglandins, which are implicated in the pathogenesis of neurodegenerative disorders. Beyond its anti-inflammatory actions, melittin promotes neurogenesis, potentially through the modulation of the BDNF/Trk-B/CREB signaling pathway, which plays a crucial role in neuronal survival and plasticity. These properties suggest that melittin not only provides symptomatic relief but could also address the root causes of neuronal degeneration, presenting a promising avenue for the development of new treatments for neurodegenerative diseases. Further research is required to validate its efficacy and safety in clinical settings.